Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Longeveron Inc (LGVNR)

Longeveron Inc (LGVNR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Longeveron Announces 1-for-10 Reverse Stock Split GlobeNewswire - Mon Aug 24, 3:05PM CDT

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer GlobeNewswire - Wed Aug 19, 3:05PM CDT

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19,...

LGVN : 6.72 (-1.18%)
DERM : 7.47 (-0.80%)
IRD : 3.69 (-4.16%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update GlobeNewswire - Wed Aug 12, 3:05PM CDT

On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition GlobeNewswire - Tue Aug 11, 8:05AM CDT

Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI,...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 GlobeNewswire - Mon Aug 3, 3:05PM CDT

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors GlobeNewswire - Thu Jul 23, 8:15AM CDT

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease GlobeNewswire - Mon Jul 13, 6:05AM CDT

Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Marie Washburn as Chief Financial Officer GlobeNewswire - Mon Jul 6, 3:05PM CDT

Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectors Corporate focus on delivering top-line results from the Phase 2b clinical trial evaluating...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) GlobeNewswire - Thu Jun 18, 8:20AM CDT

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) GlobeNewswire - Tue Jun 9, 8:20AM CDT

MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 6.72 (-1.18%)
LGVNR : 0.0005 (-37.50%)

Barchart Exclusives

Apple Was Always 1 Step Behind in AI. In Chipmaking, It’s Now 1 Step Ahead. Barchart - Sat Aug 29, 3:30PM CDT
Apple beat rivals to a 2nm chip with the M6, betting AI's future runs on your device rather than the cloud. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.